-
Product Insights
NewOligodendroglioma – Drugs In Development, 2024
Empower your strategies with our Oligodendroglioma – Drugs In Development, 2024 report and make more profitable business decisions. Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy. The Oligodendroglioma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewArrhythmias – Drugs In Development, 2024
Empower your strategies with our Arrhythmias – Drugs In Development, 2024 report and make more profitable business decisions. An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness; fainting or nearly fainting; sweating; shortness of breath; and chest pain. Treatment includes anti-arrhythmics and anticoagulants. The Arrhythmias drugs in development market research report provide...
-
Product Insights
NewB-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack...
-
Product Insights
NewGliosarcoma – Drugs In Development, 2024
Empower your strategies with our Gliosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Common symptoms are headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the...
-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewMerkel Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Merkel Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and...
-
Product Insights
NewExtranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Extranodal marginal zone B-cell lymphoma (EMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare type of non-Hodgkin lymphoma that originates in the marginal zone B cells outside of the lymph nodes. It often develops in various extranodal sites of the body, particularly mucosal tissues such as the stomach, salivary glands, lungs,...
-
Product Insights
NewNonmelanomatous Skin Cancer – Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...